Clinical Trial Update: A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence [Phase 3]

View source ↗

Summary

Phase 3 trial comparing probuphine bioavailability and safety to sublingual buprenorphine in opioid dependence was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Dependence

Drugs mentioned

• Buprenorphine (sublingual formulation) (buprenorphine)
• Probuphine (buprenorphine implant)

Snippet

Sponsor: Titan Pharmaceuticals | Conditions: Opioid Dependence | Phase 3 | Status: TERMINATED